The Department of Defense Office of Inspector General (DoD OIG) publicly released a management advisory on June 18, 2024, addressing the limitations of DoD systems in tracking funding allocated to Chinese research laboratories conducting research on "pathogens of pandemic potential." This review was conducted in response to Public Law 118-31, “National Defense Authorization Act for Fiscal Year 2024,” section 252. The advisory aims to inform Congress and DoD leadership about the results of this review, highlighting the need for improved oversight and accountability in the allocation and tracking of such funds[1][2][3][4][5].
Key Limitations
The Department of Defense Office of Inspector General (DoD OIG) identified several specific limitations in the DoD's tracking of funding allocated to Chinese research laboratories conducting research on "pathogens of pandemic potential." These limitations include:
1. Inadequate Tracking Systems: The DoD's current tracking systems are insufficient to fully account for the extent of funds provided to Chinese research laboratories. This inadequacy has led to significant gaps in data quality, making it difficult to trace specific funding allocations[6][8].
Commenti